Key facts
- Heron Pharmaceutical’s last known valuation is $377.9M (Dec 2025).
- It has raised $46.2M; the latest was Later Stage VC ($19.8M) in Dec 2025.
- Notable investors include DPH Capital, Guosheng Capital, SUNNOVO, Tibet Dorui Pharmaceutical, Xi'an Manareco.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Heron Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Heron Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Heron Pharmaceutical
Developer and provider of pharmaceutical R&D services and specialty drug development solutions designed for the discovery and optimization of innovative, modified, and generic medicines. The company provides integrated preclinical development services-including API and formulation process development, quality and stability studies-as well as technology transfer and consulting, enabling biopharma clients to accelerate drug development and regulatory readiness.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2013
- Employees
- 344
- Website
- heronpharma.cn/
- Ownership
- Privately Held (backing)
Heron Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heron Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heron Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.